GLP-1 RA initiation versus metformin and risk of cardiomyopathy in patients with cancer and diabetes treated with chemotherapy, radiation, or immunotherapy: a target trial emulation
Authors' conclusion
GLP-1 RA initiation was associated with a lower risk of cardiomyopathy compared with metformin among patients with cancer and T2D, supporting a potential role for GLP-1 RA in cardio-oncology prevention strategies.
Study context
- Population
- Adults aged 18–75 years with cancer and T2D, with prior exposure to chemotherapy, radiation, or immunotherapy; initiation between January 2006 and July 2024matched
- Participants
- 10,382 adults
- Exposure
- GLP-1 RA initiation vs metformin initiation
- Outcome
- Incident cardiomyopathy
- Follow-up
- 18.5 years
Methodological detailstarget trial emulation, 1:1 propensity score-matched, global electronic health record database
- Target trial emulation
- 1:1 propensity score-matched
- Global electronic health record database
Main finding
As reported in the abstract
Cardiomyopathy risk
Each group vs metforminHazard ratio (95% CI)
GLP-1 RA
0.43(0.24–0.76)
- GLP-1 RA
- Risk differences (RD) - 0.64% (95% CI - 0.90 to - 0.30)
Observational data: associations, not effects.
Further findings
- Results were consistent across high-risk subgroups
Original publication
GLP-1 RA initiation versus metformin and risk of cardiomyopathy in patients with cancer and diabetes treated with chemotherapy, radiation, or immunotherapy: a target trial emulation. Diabetes Res Clin Pract. Published 26 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →